Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

PATENTS

European patent protection for medical uses of known products and drug repurposing

Obtaining European patent protection for medical uses of known products is not a key factor limiting repurposing activity.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: EPO medical use patents with independent claims directed to medical uses of known products from 2001 to 2021, plotted by publication date of the patent grant (Search ID: S3).
Fig. 2: Organizations with the highest count of patents with EPO medical use independent claims (S3) and organizations owning medical use patents with family country counts of at least 20 jurisdictions (S8) in the last 20 years.
Fig. 3: Jurisdictions where patents in the same simple patent family as S8 are protected (the collection of patent documents considered to cover the same invention and all having exactly the same priorities as the S8 EPO medical use patent).
Fig. 4: Number of EPO medical use patents by Cooperative Patent Classification (CPC) class.
Fig. 5: Results of expert review manual classification of medical use patents based on the disease claimed on the broadest independent claim.

References

  1. Ashburn, T. T. & Thor, K. B. Nat. Rev. Drug Discov. 3, 673–683 (2004).

    CAS  Article  PubMed  Google Scholar 

  2. Pushpakom, S. et al. Nat. Rev. Drug Discov. 18, 41–58 (2019).

    CAS  Article  PubMed  Google Scholar 

  3. Association of Medical Research Charities. Facilitating adoption of off-patent, repurposed medicines into NHS clinical practice (AMRC, 2017).

  4. Halabi, S. F. Yale J. Law Technol. 20, 1–51 (2018).

    Google Scholar 

  5. Breckenridge, A. & Jacob, R. Nat. Rev. Drug Discov. 18, 1–2 (2019).

    CAS  Article  PubMed  Google Scholar 

  6. Aboy, M., Liddell, K., Liddicoat, J., Crespo, C. & Jordan, M. Nat. Biotechnol. 39, 1336–1343 (2021).

    CAS  Article  PubMed  Google Scholar 

  7. Deng, Y. Eur. Econ. Rev. 51, 1785–1812 (2007).

    Article  Google Scholar 

  8. Bubela, T. et al. Nat. Biotechnol. 31, 202–206 (2013).

    CAS  Article  PubMed  Google Scholar 

  9. Smith, J. A. et al. Nat. Biotechnol. 36, 1043–1047 (2018).

    CAS  Article  PubMed  Google Scholar 

  10. Aboy, M., Liddell, K., Liddicoat, J. & Crespo, C. Nat. Biotechnol. 34, 1119–1123 (2016).

    CAS  Article  PubMed  Google Scholar 

  11. Aboy, M., Liddicoat, J., Liddell, K., Jordan, M. & Crespo, C. Nat. Biotechnol. 35, 820–825 (2017).

    CAS  Article  PubMed  Google Scholar 

  12. Aboy, M., Crespo, C., Liddell, K., Liddicoat, J. & Jordan, M. Nat. Biotechnol. 36, 1146–1149 (2018).

    CAS  Article  PubMed  Google Scholar 

  13. EPO Guidelines for Examination. G.VI.7.1 First or further medical use of known products (EPO, 1 March 2021).

  14. Kesselheim, A. S., Tan, Y. T. & Avorn, J. Health Aff. (Millwood) 34, 286–293 (2015).

    Article  Google Scholar 

  15. Bühling, J. Patent Protection for Second Medical Uses (AIPPI Law Series) 2nd edn (Kluwer Law International, 2020).

Download references

Acknowledgements

The research was supported, in part, by a Novo Nordisk Foundation Grant for a scientifically independent Collaborative Research Programme in Biomedical Innovation Law (grant no. NNF17SA027784).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mateo Aboy.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Aboy, M., Liddell, K., Jordan, M. et al. European patent protection for medical uses of known products and drug repurposing. Nat Biotechnol 40, 465–471 (2022). https://doi.org/10.1038/s41587-022-01269-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-022-01269-3

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing